June 4, 2020 / 2:00 AM / a month ago

BRIEF-Dimerix Says Dmx-200 Selected For Inclusion In The Remap-Cap Global Study Protocol

June 4 (Reuters) - Dimerix Ltd:

* DMX-200 SELECTED FOR INCLUSION IN THE REMAP-CAP GLOBAL STUDY PROTOCOL FOR ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19

* SUBJECT TO APPROVALS, CO WILL SUPPLY DRUG PRODUCT FROM ITS EXISTING GMP BATCH OF DMX-200

* RANDOMISED, EMBEDDED, MULTIFACTORIAL ADAPTIVE PLATFORM TRIAL FOR COMMUNITY-ACQUIRED PNEUMONIA (REMAP-CAP) CLINICAL STUDY IS ENDORSED BY WHO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below